In addition, among the enriched signaling pathways, including those of necroptosis, MAPK, NOD-like receptor, focal adhesion, small cell lung cancer, GnRH, IL-17, TNF, apoptosis, ECM-receptor interaction, choline metabolism in cancer, and linoleic acid metabolism (Figure 6B), many have not been reported for their involvement in the anticancer effects of other cardiac glycosides. This evidence concerns the gene IL17A and small cell lung carcinoma.